Friday Jul 25
Will This Price Target Increase Help Celgene (CELG) Stock Today?
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
Friday Jul 25
Flexion Therapeutics Announces Board Changes
Flexion Therapeutics, Inc. announced today changes to the composition of its Board of Directors.
Thu Jul 24, 2014
Press release distribution, EDGAR filing, XBRL, regulatory filings
Sales grew 4.9 percent yea... )--Coca-Cola Enterprises, Inc. today reported second-quarter operating income of $295 million on a reported basis, or $341 million on a comp... )--Celgene Corporation reported net product sales of $1,845 million for the second quarter of 2014, an 18 percent increase from the same period in 2013.
Biotechs beat estimates, but the Street wants more
It's not easy being a biotech company these days. Just ask Alexion Pharmaceuticals Inc., Celgene Corp. and Gilead Sciences Inc. blew past earnings expectations when it reported late Wednesday.
Why Gilead Is A Better Buy Than This Rival
We pitch two companies from the biotechnology sector, Gilead and Celgene, against one another in the latest installment of our Head-To-Head series.
Celgene (CELG) Stock Falls After Mixed Second-Quarter Earnings
Celgene reported a year-over-year increase in net profit to $597.8 million, or 72 cents a share, from $478.1 million, or 56 cents a share.
Celgene profit rises 25 pct up on higher cancer drug sales
Celgene Corp reported a 25 percent increase in quarterly profit, helped by robust sales of its flagship cancer drug, Revlimid.
Investor's Business Daily
Celgene Reports Second Quarter 2014 Operating and Financial Results
Celgene Corporation reported net product sales of $1,845 million for the second quarter of 2014, an 18 percent increase from the same period in 2013.
Cramer's Mad Money: The 4 Horsemen Trample Big Pharma
The Four Horsemen Are Trampling Over Big Pharma: Regeneron , Gilead , Biogen Idec , Celgene , GlaxoSmithKline The days of big pharma names like GlaxoSmithKline may be giving way to smaller, stronger biotechs, such as Cramer's "Four Horsemen": Regeneron , Gilead , Biogen Idec and Celgene .
Wed Jul 23, 2014
The Motley Fool
Earnings Preview: Bristol-Myers Squibb and Celgene Corporation
Most health care stocks have been experiencing a roller coaster ride so far this year.
Biogen's great earnings could spur more inflated biotech stock prices
If second quarter earnings reported tonight by Gilead , and tomorrow morning by Celgene , are as good as what we saw from Biogen Idec this morning, you can bank on a reinflation of the biotech bubble for the next several months to come.
Celgene (CELG) Scheduled to Post Earnings on Thursday
Celgene is set to post its Q214 quarterly earnings results on Thursday, July 24th.
Tue Jul 22, 2014
Scientists find that cancer-fighting drug romidepsin aids in detection of HIV
Scientists from Aarhus University in Demark have found that cancer-fighting Istodax, also known as romidepsin and produced by Celgene Corp., activates the HIV virus that hides in CD4 cells.
Fri Jul 18, 2014
Biotech Enters Reporting Season With Large Caps Central To Sector Performance
Biotech stock stocks enter their earnings season with investors increasingly interested in the long-term outlook for product pipelines, although large-cap growth stocks remain central to the sectors performance, an analyst said Friday.
Wed Jul 16, 2014
Some Elegant Biotech Platforms I Read About While Looking For The Next Regeneron
Discovery and development platforms can efficiently multiply a drug pipeline. Regeneron leveraged its platforms to become a biotech paragon over the 5 years prior to 2014.
Thu Jul 10, 2014
Cramer's Mad Money - The 4 Horsemen Of Biotech Ride On
Cramer consulted the technical analysis of Bob Lang to see what the charts are saying about the "Four Horsemen of Biotech": Celgene , Regeneron , Biogen Idec and Gilead .
Wed Jul 09, 2014
Stock Market Today: July 9, 2014
Stocks to Watch from The Survey - Second-quarter earnings season kicked off after the market closed yesterday, when Alcoa released June-period financials.
Two Analysts Don't See Celgene's Weak Trial Results As A Huge Setback
Shares of Celgene have been volatile since the company announced weak Phase III trial results for OTEZLA Wednesday morning.
Celgene Corporation's OTEZLA Misses Mark In Phase 3 Spinal Arthritis Study
Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLAA in Ankylosing Spondylitis Phase III POSTURE Study Did Not Achieve Primary Endpoint of ASAS 20 at Week 16 Based on Efficacy and Safety Data at Week 24, the Independent Data Monitoring Committee Recommended Continuation of the Phase III POSTURE Study Without Change In ... (more)